Company Filing History:
Years Active: 1997-2003
Title: Innovations of Thomas E. Keane
Introduction
Thomas E. Keane is a notable inventor based in Dunwoody, Georgia, with a focus on advancements in medical therapies. He holds three patents that contribute significantly to the field of urogenital cancer treatment. His work emphasizes the use of boron neutron capture therapy (BNCT) to enhance treatment efficacy for various urogenital tumors.
Latest Patents
Keane's latest patents include innovative methods and compositions for treating urogenital tumors, particularly cancer of the prostate, bladder, and kidney. His patents detail the use of boron-containing compounds that are sufficiently lipophilic to penetrate urogenital membranes effectively. Notable compounds mentioned in his patents include 5-carboranyl-2'-deoxyuridine and 5-o-carboranyl-1-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)uracil. These compounds are designed to accumulate in target tumors and are activated through irradiation with low-energy neutrons, enhancing the therapeutic effects of BNCT.
Career Highlights
Throughout his career, Thomas E. Keane has worked with esteemed institutions such as Emory University. His research has focused on developing innovative therapies that leverage the unique properties of boron compounds in cancer treatment. His contributions to the field have been recognized through his patents and ongoing research efforts.
Collaborations
Keane has collaborated with notable figures in the field, including Dennis C. Liotta and Raymond F. Schinazi. These collaborations have furthered the development of his innovative approaches to cancer treatment.
Conclusion
Thomas E. Keane's work in the realm of urogenital cancer treatment through boron neutron capture therapy represents a significant advancement in medical innovation. His patents and collaborations highlight his commitment to improving therapeutic outcomes for patients facing challenging diagnoses.